VRNA vs. PRGO, CRNX, CORT, AXSM, RARE, PBH, HCM, MRUS, ARWR, and FOLD
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Merus (MRUS), Arrowhead Pharmaceuticals (ARWR), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Verona Pharma (NASDAQ:VRNA) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking.
Perrigo received 453 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 79.95% of users gave Verona Pharma an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Verona Pharma has a net margin of 0.00% compared to Perrigo's net margin of -0.17%. Perrigo's return on equity of 6.96% beat Verona Pharma's return on equity.
Verona Pharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Verona Pharma currently has a consensus price target of $33.50, suggesting a potential upside of 176.17%. Perrigo has a consensus price target of $40.67, suggesting a potential upside of 50.95%. Given Verona Pharma's higher probable upside, research analysts clearly believe Verona Pharma is more favorable than Perrigo.
In the previous week, Perrigo had 2 more articles in the media than Verona Pharma. MarketBeat recorded 4 mentions for Perrigo and 2 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.20 beat Perrigo's score of 1.11 indicating that Verona Pharma is being referred to more favorably in the media.
85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by company insiders. Comparatively, 0.7% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Perrigo has higher revenue and earnings than Verona Pharma. Perrigo is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Perrigo beats Verona Pharma on 9 of the 17 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
